PL2928454T3 - Triazyny do leczenia chorób wywoływanych przez pierwotniaki - Google Patents

Triazyny do leczenia chorób wywoływanych przez pierwotniaki

Info

Publication number
PL2928454T3
PL2928454T3 PL13802596T PL13802596T PL2928454T3 PL 2928454 T3 PL2928454 T3 PL 2928454T3 PL 13802596 T PL13802596 T PL 13802596T PL 13802596 T PL13802596 T PL 13802596T PL 2928454 T3 PL2928454 T3 PL 2928454T3
Authority
PL
Poland
Prior art keywords
protozoa
triazines
treatment
diseases caused
diseases
Prior art date
Application number
PL13802596T
Other languages
English (en)
Inventor
Hamadi Karembe
Roman Krejci
Jérôme GUYONNET
Hannelie Cilliers
Original Assignee
CEVA Santé Animale SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47351540&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2928454(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by CEVA Santé Animale SA filed Critical CEVA Santé Animale SA
Publication of PL2928454T3 publication Critical patent/PL2928454T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Dispersion Chemistry (AREA)
PL13802596T 2012-12-07 2013-12-06 Triazyny do leczenia chorób wywoływanych przez pierwotniaki PL2928454T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12306546.8A EP2740469A1 (en) 2012-12-07 2012-12-07 New treatments with triazines
PCT/EP2013/075755 WO2014086958A1 (en) 2012-12-07 2013-12-06 New treatments with triazines
EP13802596.0A EP2928454B1 (en) 2012-12-07 2013-12-06 Triazines for treating protozoan diseases

Publications (1)

Publication Number Publication Date
PL2928454T3 true PL2928454T3 (pl) 2020-08-24

Family

ID=47351540

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13802596T PL2928454T3 (pl) 2012-12-07 2013-12-06 Triazyny do leczenia chorób wywoływanych przez pierwotniaki

Country Status (23)

Country Link
US (1) US9877969B2 (pl)
EP (3) EP2740469A1 (pl)
JP (1) JP6125034B2 (pl)
KR (1) KR102253497B1 (pl)
CN (3) CN113144202A (pl)
AU (1) AU2013353982B2 (pl)
BR (3) BR122021005311B1 (pl)
CA (1) CA2892886C (pl)
CL (1) CL2015001563A1 (pl)
CY (1) CY1123190T1 (pl)
DK (1) DK2928454T3 (pl)
ES (1) ES2778950T3 (pl)
FR (1) FR20C1044I2 (pl)
HR (1) HRP20200630T1 (pl)
HU (2) HUE049950T2 (pl)
MX (1) MX387072B (pl)
NL (1) NL301064I2 (pl)
PH (1) PH12015501220B1 (pl)
PL (1) PL2928454T3 (pl)
PT (1) PT2928454T (pl)
RU (1) RU2696265C2 (pl)
SI (1) SI2928454T1 (pl)
WO (1) WO2014086958A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007025908A1 (de) 2007-06-01 2008-12-04 Bayer Healthcare Ag Formulierungen enthaltend Triazinone und Eisen
EP2740469A1 (en) 2012-12-07 2014-06-11 Ceva Sante Animale New treatments with triazines
EP2740470A1 (en) * 2012-12-07 2014-06-11 Ceva Sante Animale Treatment of Coccidiosis with intramuscular triazine composition
EP2740492A1 (en) 2012-12-07 2014-06-11 Ceva Sante Animale Triazine formulations with a second active ingredient and surfactant(s)
EP3578181A1 (en) 2018-06-05 2019-12-11 Bayer Animal Health GmbH Formulation for use in the simultaneous treatment of coccidial infections and iron deficiencies
EP3578182A1 (en) 2018-06-05 2019-12-11 Bayer Animal Health GmbH Formulations containing triazinones and iron with a low amount of free iron ions

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1183940A (en) 1966-10-22 1970-03-11 Fisons Pharmaceuticals Ltd Ferric Hydroxide Complexes
DE2718799A1 (de) 1977-04-27 1978-11-09 Bayer Ag 1-(4-phenoxy-phenyl)-1,3,5-triazin- derivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel und wachstumsfoerderer
US4493826A (en) * 1982-01-25 1985-01-15 Schering Corporation Gentamicin-gleptoferron compositions
DE3300793A1 (de) 1983-01-12 1984-07-12 Bayer Ag, 5090 Leverkusen Coccidiosemittel
US5219853A (en) 1983-01-12 1993-06-15 Bayer Aktiengesellschaft Agent for coccidiosis
DE3516632A1 (de) 1985-05-09 1986-11-13 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von 1,3,5-triazintrionen
JPH0776524A (ja) * 1993-07-13 1995-03-20 Takeda Chem Ind Ltd 動物用抗貧血剤
DE19603984A1 (de) 1996-02-05 1997-08-07 Bayer Ag Granulate von Triazinen
DE19603954C2 (de) 1996-02-05 2003-04-17 Wagon Automotive Gmbh Prallträger für ein Kraftfahrzeug
DE19824483A1 (de) 1998-06-02 1999-12-09 Bayer Ag Halbfeste wäßrige Zubereitungen für orale Applikation von Toltrazuril-Sulfon
MXPA01003542A (es) 1998-10-08 2002-09-18 New Ace Res Company Composiciones y metodos nuevos para la prevencion y tratamiento de enfermedad causada por protozoarios.
WO2001026660A1 (en) 1999-10-08 2001-04-19 New Ace Research Company Novel compositions and methods for prevention and treatment of protozoal disease
DE10040174A1 (de) * 2000-08-17 2002-02-28 Bayer Ag Verwendung von Triazintrion-Sulfonen zur Bekämpfung von Coccidiosen
EP1819383A4 (en) 2004-12-01 2010-08-18 Acushot Inc INJECTOR WITHOUT NEEDLE
NZ573225A (en) 2006-06-07 2012-02-24 Acushot Inc Charging mechanism for a needle-free injector with a piston actuator driven by a gas charge
DE102006038292A1 (de) 2006-08-16 2008-02-21 Bayer Healthcare Ag Transdermale Anwendung von Triazinen zur Bekämpfung von Coccidien-Infektionen
DE102007025908A1 (de) 2007-06-01 2008-12-04 Bayer Healthcare Ag Formulierungen enthaltend Triazinone und Eisen
BRPI0910250A2 (pt) 2008-03-07 2015-09-29 Pharmajet Inc injetor intradérmico e usos do mesmo
SI22751A (sl) 2008-04-03 2009-10-31 Krka, D.D., Novo Mesto Toltrazuril z izboljĺ animi lastnostmi za raztapljanje
FR2946882B1 (fr) 2009-06-18 2011-08-26 Ceva Sante Animale Suspension veterinaire gelifiee de fer
CN101947201B (zh) 2010-09-08 2011-12-28 洛阳惠中兽药有限公司 兽药纳米混悬剂及其制备方法与应用
CN102512366A (zh) 2011-12-28 2012-06-27 广州市和生堂动物药业有限公司 妥曲珠利悬浮乳剂及其制备方法
CN102743334A (zh) 2012-07-30 2012-10-24 郑州后羿制药有限公司 一种妥曲珠利注射剂及其制备方法
EP2740470A1 (en) * 2012-12-07 2014-06-11 Ceva Sante Animale Treatment of Coccidiosis with intramuscular triazine composition
EP2740492A1 (en) 2012-12-07 2014-06-11 Ceva Sante Animale Triazine formulations with a second active ingredient and surfactant(s)
EP2740469A1 (en) 2012-12-07 2014-06-11 Ceva Sante Animale New treatments with triazines
EP3578181A1 (en) 2018-06-05 2019-12-11 Bayer Animal Health GmbH Formulation for use in the simultaneous treatment of coccidial infections and iron deficiencies

Also Published As

Publication number Publication date
CN113144202A (zh) 2021-07-23
JP6125034B2 (ja) 2017-05-10
FR20C1044I1 (pl) 2020-10-30
ES2778950T3 (es) 2020-08-12
DK2928454T3 (da) 2020-03-30
HRP20200630T1 (hr) 2020-07-10
NL301064I2 (nl) 2021-03-03
CA2892886A1 (en) 2014-06-12
KR20150104565A (ko) 2015-09-15
US20150313905A1 (en) 2015-11-05
CL2015001563A1 (es) 2015-10-23
KR102253497B1 (ko) 2021-05-21
AU2013353982B2 (en) 2018-01-04
EP2928454A1 (en) 2015-10-14
BR122021005311B1 (pt) 2022-01-25
BR122021005310B1 (pt) 2022-01-25
CN104981233A (zh) 2015-10-14
AU2013353982A1 (en) 2015-06-11
EP2740469A1 (en) 2014-06-11
EP3721869A1 (en) 2020-10-14
CA2892886C (en) 2021-09-07
HUE049950T2 (hu) 2020-11-30
MX387072B (es) 2025-03-19
CN112370454A (zh) 2021-02-19
RU2015127025A (ru) 2017-01-12
HUS2000037I1 (hu) 2020-10-28
PH12015501220A1 (en) 2015-08-17
US9877969B2 (en) 2018-01-30
PT2928454T (pt) 2020-04-23
WO2014086958A1 (en) 2014-06-12
FR20C1044I2 (fr) 2021-10-15
BR112015013182A2 (pt) 2017-07-11
RU2696265C2 (ru) 2019-08-01
EP2928454B1 (en) 2020-03-18
JP2016501252A (ja) 2016-01-18
CY1123190T1 (el) 2021-10-29
PH12015501220B1 (en) 2015-08-17
SI2928454T1 (sl) 2020-07-31
MX2015007128A (es) 2015-10-14

Similar Documents

Publication Publication Date Title
LTC2785706I2 (lt) Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui
IL289300A (en) Combination therapy for treating cancer
IL262956B (en) Methods for increasing efficacy of folr1 cancer therapy
LT2885010T (lt) Tautopatijos gydymo būdai
SMT201700003B (it) Didropiridoni come inibitori del fattore xia
HUE061618T2 (hu) Vegyület szemrendellenességek kezelésére
HRP20181679T1 (hr) Amidni spojevi za liječenje hiv
HUE037048T2 (hu) Eljárások 4-cikloalkiloxibenzolszulfonamidok elõállítására
LT2887944T (lt) Alopregnanolonas, skirtas atsparios epileptinės būklės gydymui
EP2864360A4 (en) TARGETED THERAPEUTICS
DK2919796T3 (da) Brug af akkermansia til behandling af stofskiftesygdomme
EP2873047A4 (en) APPROVAL OF TRANSACTIONS
PL2839230T3 (pl) Instalacja do obróbki obiektów
HUS2000037I1 (hu) Triazinok Protozoa okozta betegségek kezelésére
BR112013033974A2 (pt) terapia de combinação
DK2872497T4 (da) Chromanyl-derivater til behandling af mitokondriel sygdom
EP2863748A4 (en) 1,2,4-triazine-6-CARBOXAMIDKINASEINHIBITOREN
HRP20181481T1 (hr) D-metadon za liječenje psihijatrijskih simptoma
EP2912186A4 (en) TARGETED THROMBOZYTE TREATMENT
LT2914254T (lt) Kombinacinės terapijos chemoresistencinių vėžių gydymui
HUE046508T2 (hu) Orvepitant krónikus viszketés kezelésére
IL234606B (en) Novel methods and composition for treatment of disease
LT2812013T (lt) Kompozicija, skirta džs gydymui
HRP20181799T1 (hr) Optimizirana farmaceutska formula, namijenjena liječenju upalnih promjena jednjaka
DK2900259T3 (da) Glycosidase-regime til behandling af infektionssygdomme